What is the fine-grained topic of the following text: Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study., with Donald Jones, P Boudes, C Bowlus, M Galambos, B Bacon, Y Doerffel, N Gitlin, S Gordon, J Odin, D Sheridan, M Wörns, V Clark, L Corless, H Hartmann, M Jonas, A Kremer, G Mells, P Buggisch, B Freilich, Cynthia Levy, J Vierling, D Bernstein, M Hartleb, E Janczewska, F Rochling, H Shah, M Shiffman, J Smith, Y Choi, A Steinberg, M Varga, H Chera, R Martin, C McWherter, G Hirschfield, 2 The lancet. Only return the topic.
The topic of the text is a Phase 2 clinical study on the efficacy of Seladelpar (MBX-8025) in treating patients with primary biliary cholangitis who have had an inadequate response to ursodeoxycholic acid.